Johnson & Johnson (JNJ)

NYSE: JNJ · IEX Real-Time Price · USD
163.42
+1.42 (0.88%)
At close: Jan 31, 2023, 4:00 PM
163.08
-0.34 (-0.21%)
Pre-market: Feb 1, 2023, 6:49 AM EST
0.88%
Market Cap 427.26B
Revenue (ttm) 96.04B
Net Income (ttm) 19.16B
Shares Out 2.61B
EPS (ttm) 7.18
PE Ratio 22.76
Forward PE 16.89
Dividend $4.45 (2.72%)
Ex-Dividend Date Nov 21, 2022
Volume 11,501,250
Open 161.70
Previous Close 162.00
Day's Range 161.05 - 163.43
52-Week Range 155.72 - 186.69
Beta 0.57
Analysts Buy
Price Target 188.75 (+15.5%)
Earnings Date Jan 24, 2023

About JNJ

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; N... [Read more]

Sector Healthcare
IPO Date Sep 24, 1944
Employees 141,700
Stock Exchange NYSE
Ticker Symbol JNJ
Full Company Profile

Financial Performance

In 2022, JNJ's revenue was $93.78 billion, an increase of 13.55% compared to the previous year's $82.58 billion. Earnings were $20.88 billion, an increase of 41.89%.

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $188.75, which is an increase of 15.50% from the latest price.

Price Target
$188.75
(15.50% upside)
Analyst Consensus: Buy
Stock Forecasts

News

The 7 Best Climate Change Stocks to Buy for 2023

The concept of best climate change stocks to buy for 2023 presents a critically ethical tone. According to multiple scientists and investigative reports, human-caused environmental impact imposed many...

Other symbols: BIRDDISHONIBMMDLZUL
12 hours ago - InvestorPlace

J&J Faces Longer Path to Resolving Talc Lawsuits

The company's court loss over baby-powder litigation could force it to defend thousands of lawsuits case by case, just as it navigates the biggest restructuring in its 137-year history.

14 hours ago - WSJ

J&J (JNJ) Down as Court Rejects Bankruptcy Claim in Talc Lawsuits

A federal appeals court rejects J&J's (JNJ) efforts to shift over 38,000 lawsuits related to its talcum-based baby powder out of trial courts and into bankruptcy court.

18 hours ago - Zacks Investment Research

5 Dividend King Stocks Gurus Are Feasting On

According to the All-in-one Screener, a Premium feature of GuruFocus, five dividend kings stocks that have high guru ownership as of the third-quarter 2022 13F portfolio filings are Johnson & Johnson ...

Other symbols: ABBVKOPEPPG
18 hours ago - GuruFocus

Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits

Nachawati Law Group: Ovarian cancer victims deserve day in court PHILADELPHIA , Jan. 30, 2023 /PRNewswire/ -- Trial lawyers with the Nachawati Law Group praised a ruling by the U.S. Court of Appeals f...

21 hours ago - PRNewsWire

Court tosses bankruptcy petition by Johnson & Johnson's talc unit

An appeals court on Monday dismissed the Chapter 11 bankruptcy petition of J&J's talc subsidiary, which the company formed to resolve thousands of lawsuits.

1 day ago - Fox Business

Johnson And Johnson Stock Slips After Missing The Mark For Earnings

Johnson and Johnson's stock took a tumble before its Q4 2022 earnings call, and the numbers reported didn't help it bounce back. Here's what happened.

1 day ago - Forbes

Johnson & Johnson stock drops following dismissal of bankruptcy strategy tied to talc lawsuits

#Johnson&Johnson #J&J Yahoo Finance anchors Allie Canal, Seana Smith, and Dave Briggs report on Johnson & Johnson stock down slightly on Monday afternoon over concern of the fallout from the talcum po...

1 day ago - Yahoo Finance

Johnson and Johnson loses $17 billion in market value after appeals court denies company bankruptcy escape in baby powder lawsuits

Johnson & Johnson continues to stand by the safety of its baby powder formula and has denied that it contains cancer-causing asbestos.

1 day ago - Business Insider

Why Is Johnson & Johnson (JNJ) Stock Down Today?

It's a sea of red in the stock market today, but some companies are clearly under-performing others. One such notable decliner today is Johnson & Johnson (NYSE: JNJ), with shares of JNJ stock droppin...

1 day ago - InvestorPlace

Appeals court dismisses Johnson and Johnson talc bankruptcy case

CNBC's Meg Tirrell joins 'Halftime Report' to report on the U.S. appeals court decision to toss out Johnson and Johnson's talc powder settlements in to a bankruptcy case, the reasons behind the ruling...

1 day ago - CNBC Television

J&J's Talc Bankruptcy Case Thrown Out by Appeals Court

A federal appeals court said Johnson & Johnson's LTL Management can't use bankruptcy to resolve numerous talc-injury lawsuits.

1 day ago - WSJ

Johnson & Johnson's talc bankruptcy case rejected by appeals court

Johnson & Johnson's strategy to use bankruptcy to resolve the multibillion-dollar litigation over claims its talc products cause cancer was rejected by a federal appeals court on Monday, but the healt...

1 day ago - New York Post

Johnson & Johnson stock takes a dive after WSJ report that federal appeals court rejected talc bankruptcy case

Shares of Johnson & Johnson JNJ, -2.56% took a dive in midday trading Monday, after The Wall Street Journal reported that a federal appeals court rejected the consumer products and drug maker's move t...

1 day ago - Market Watch

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

1 day ago - Zacks Investment Research

Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?

Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today's market. They offer relatively high yields and at least some value while projec...

Other symbols: ABT
5 days ago - MarketBeat

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.

Other symbols: EDITELEVFATEIPSCYMAB
6 days ago - MarketBeat

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

6 days ago - Zacks Investment Research

J&J Gets Ready to Break up With Tylenol

Johnson & Johnson's consumer business was the only division to deliver growth in the fourth quarter.

1 week ago - WSJ

‘Tripledemic' demand for Motrin and Tylenol fueled year-end sales in J&J's consumer business

As cases of COVID, flu and respiratory syncytial virus surged in the fall as part of a “tripledemic” in the U.S., demand for cold medications translated to a good quarter for Johnson & Johnson's JNJ c...

1 week ago - Market Watch

Johnson & Johnson fourth-quarter earnings down 25%

The company continues to see pressure on sales from staffing shortages at hospitals, which have limited growth in procedures using J&J products, while inflation has boosted expenses.

1 week ago - Fox Business

J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat

J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.

1 week ago - Zacks Investment Research

Q4 Earnings Season Heats Up: JNJ, MMM, GE & More

Whether pre-market futures are reacting to results or just doing some profit-taking off recent highs is hard to tell -- the Dow is -150 points at this hour, the S&P 500 is -20 and the Nasdaq -85 point...

Other symbols: GEMMMTRV
1 week ago - Zacks Investment Research

J&J CFO on Earnings Forecast, Costs and Consumer Spinoff

Johnson & Johnson CFO Joseph Wolk discusses the company's stronger-than-expected earnings forecast for 2023 and cost pressures with Guy Johnson and Alix Steel on "Bloomberg Markets." Follow Bloomberg ...

1 week ago - Bloomberg Markets and Finance

Johnson & Johnson reports mixed earnings, strong consumer demand

#Johnson&Johnson Yahoo Finance's Anjalee Khemlani joins the Live show to discuss fourth-quarter earnings for Johnson & Johnson.

1 week ago - Yahoo Finance